The company’s key strengths include a well‑established oncology franchise with cabozantinib, sharply improving profitability backed by strong operating and free cash flow, and a conservative balance sheet with low debt and ample liquidity. Its focused scientific expertise in kinase biology, coupled with an expanding presence in advanced biologics and ADCs, provides a differentiated technological base. The robust cash generation supports heavy R&D investment and sizable share repurchases without straining the balance sheet.

Major risks center on concentration and transition. Exelixis remains heavily reliant on cabozantinib, which faces competitive threats from newer therapies and eventual generic entry. The balance sheet shows negative retained earnings and a gradually shrinking asset and equity base, reflecting historical losses and aggressive capital returns that have not yet been fully offset by cumulative profits. R&D and SG&A have been large and somewhat volatile, and the recent step‑down in capex and R&D spending raises questions about sustaining long‑term growth investment. As with all biotech firms, clinical and regulatory setbacks for pipeline assets—especially zanzalintinib—could materially affect future prospects.

Looking ahead, Exelixis appears to be in a transition from being a single‑franchise company to a multi‑asset oncology player. The financial statements point to a business that is currently very profitable and cash generative, with enough balance‑sheet strength to fund ambitious R&D plans. The strategic trajectory—building on cabozantinib, advancing zanzalintinib, and broadening into biologics—could support continued growth if the pipeline progresses as hoped and the company navigates competitive pressures. At the same time, the dependence on successful innovation, the need to offset future erosion of the core franchise, and signs of a slowly contracting asset base underscore that the forward path, while promising, carries meaningful execution and industry‑specific risk.